This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khan, O. A Articles by Lisak, R. P Search for Related Content PubMed PubMed Citation Articles by Khan, O. A Articles by Lisak, R. P Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

A prospective, open-label treatment trial to compare the effect of IFNß-1a (Avonex®), IFNß-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

Alexandros C Tselis

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

John A Kamholz

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

James Y Garbern

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

Richard A Lewis

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

Robert P Lisak

Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA

We previously reported results of a 12 month prospective, non-randomized, open-label treatment trial of immunomodulatory therapy in patients with relapsing-remitting multiple sclerosis (RRMS). We now report the results after 18 months of follow-up. Our primary objective was to compare the effect of INFß-1a (Avonex®), IFNß-1b (Betaseron®), and Glatiramer Acetate (GA, Copaxone®) to no treatment on the relapse rate in patients with RRMS. One hundred and fifty-six consecutive patients with clinically definite RRMS with a Kurtzke scale (EDSS) score of 4 or less were followed for 18 months. Prior 2-year relapse history and available chart information was carefully reviewed at the time of enrollment. Thirty-three of 156 elected no treatment at enrollment; 40 elected IFNß-1a, 41 IFNß-1b, and 42 chose GA. There were no statistically significant differences among the four groups at enrollment. After 18 months of treatment, 122 patients remained in their original treatment group. Compared to the untreated group (1.02), mean annualized number of relapses was significantly reduced only in the GA (0.49, P40.0001) and IFNß-1b groups (0.55, P=0.001) in contrast to the IFNß-1a treated patients (0.81, P=0.106) who did not show a significant reduction. Despite limitations of the study design, the results provide helpful clinical information regarding the relative efficacy of each therapy in mildly affected treatment naïve RRMS patients.

Key Words: multiple sclerosis • interferon beta • glatiramer acetate • relapse rate • clinical trial

Multiple Sclerosis, Vol. 7, No. 6, 349-353 (2001)
DOI: 10.1177/135245850100700601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Cadavid, L. J. Wolansky, J. Skurnick, J. Lincoln, J. Cheriyan, K. Szczepanowski, S. S. Kamin, A. R. Pachner, J. Halper, and S. D. Cook Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study Neurology, June 9, 2009; 72(23): 1976 - 1983. [Abstract] [Full Text] [PDF]

				A. Horani, N. Muhanna, O. Pappo, A. Melhem, C. E. Alvarez, S. Doron, W. Wehbi, K. Dimitrios, S. L. Friedman, and R. Safadi Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G628 - G638. [Abstract] [Full Text] [PDF]

				P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264. [Abstract] [PDF]

				E Portaccio, V Zipoli, G Siracusa, S Sorbi, and M P Amato Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria Multiple Sclerosis, June 1, 2006; 12(3): 281 - 286. [Abstract] [PDF]

				S. A. Rizvi and M. A. Agius Current approved options for treating patients with multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S8 - S14. [Abstract] [Full Text]